Maternal Health Market Projected To Experience Major Revenue Boost during 2020-2025 | Sanofi, J&J, Ageil Therapeutics, Fuji Latex, Okamoto Industries, Reckitt Benckiser

Overview of Global Maternal Health Market:

This report provides in-depth study of “Global Maternal Health Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Maternal Health Market report also provides an in-depth survey of key players in the market organization.

According to the market research study, Maternal Health is the health of women during pregnancy, childbirth, and the postpartum period. It encompasses the health care dimensions of family planning, preconception, prenatal, and postnatal care in order to ensure a positive and fulfilling experience in most cases and reduce maternal morbidity and mortality in other cases.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/270621 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

As per the regional analysis, The Maternal Health Market in North America is expected to grow at the highest CAGR during the forecast period. Moreover, the presence of major players in the Maternal Health Market ecosystem results in the increasing adoption of these systems in North America.

In the end, the report makes some important proposals for a new project of Maternal Health Market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2025 global Maternal Health market covering all important parameters.

Global Key Vendors:

1 Ageil Therapeutics

2 Fuji Latex

3 Johnson & Johnson

4 Okamoto Industries

5 Reckitt Benckiser

6 Sanofi and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Maternal Health Market Report 2020” @ https://www.businessindustryreports.com/buy-now/270621/single .

Product Type Segmentation

1 Hormones

2 Nutritives

3 Analgesics

4 Anti-Infectives

5 Others

Industry Segmentation

1 Hospitals

2 Clinics

3 Household

Global Industry News:

Sanofi (June 02, 2020) - Sarclisa (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma - Sarclisa (isatuximab) added to carfilzomib and dexamethasone (Sarclisa combination therapy) reduced the risk of disease progression or death by 47% (hazard ratio 0.531, 99% CI 0.318-0.889, p=0.0007, n=179) compared to standard of care carfilzomib and dexamethasone (Kd) in patients (n=123) with relapsed multiple myeloma (MM). Sarclisa combination therapy compared to Kd alone showed a treatment benefit consistent across multiple subgroups.

These results from the Phase 3 IKEMA trial follow the topline announcement on May 12, 2020 that Sarclisa combination therapy met the trial primary endpoint at the pre-planned interim analysis. Interim results will be presented during the late-breaking session of the European Hematology Association (EHA) Virtual Congress (EHA25) on June 14, 2020 and will form the basis for global regulatory submissions later this year.

“In the Phase 3 IKEMA trial, the addition of Sarclisa to carfilzomib and dexamethasone reduced the risk of disease progression or death by 47 percent compared to treatment with carfilzomib and dexamethasone alone,” said Philippe Moreau, M.D., Department of Hematology, University Hospital of Nantes, France. “These results suggest the potential of Sarclisa to become a new standard of care in the relapsed multiple myeloma setting.”

While median progression free survival (PFS), defined as time to disease progression or death, for Kd was 19.15 months, the median PFS for patients receiving Sarclisa combination therapy had not been reached at the time of the pre-planned interim analysis. The safety and tolerability of Sarclisa observed in this trial was consistent with the observed safety profile of Sarclisa in other clinical trials, with no new safety signals observed.

“This is the second Phase 3 trial to demonstrate superior results with Sarclisa combination therapy over a standard of care regimen, adding to the growing body of evidence that our anti-CD38 monoclonal antibody has the potential to make a meaningful difference for patients,” said John Reed, M.D., Ph.D., Global Head of Research and Development at Sanofi. “We believe Sarclisa has the potential to become the anti-CD38 of choice for the treatment of multiple myeloma. We look forward to seeing the results from future clinical trials to understand the impact of Sarclisa in earlier stages of disease.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/270621 .

Major Points in Table of Contents:

Global Maternal Health Market Report 2020

1 Maternal Health Product Definition

2 Global Maternal Health Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Maternal Health Shipments

2.2 Global Manufacturer Maternal Health Business Revenue

2.3 Global Maternal Health Market Overview

2.4 COVID-19 Impact on Maternal Health Industry

3 Manufacturer Maternal Health Business Introduction

3.1 Ageil Therapeutics Maternal Health Business Introduction

3.2 Fuji Latex Maternal Health Business Introduction

3.3 Johnson & Johnson Maternal Health Business Introduction

3.4 Okamoto Industries Maternal Health Business Introduction

3.5 Reckitt Benckiser Maternal Health Business Introduction

3.6 Sanofi Maternal Health Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.